Optimal Dose of Combination of Rocuronium and Cisatracurium
Information source: Yonsei University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Otitis Media; Anesthesia
Intervention: 10% reduction of combination of Esmeron® and Nimbex® (Drug); 20% reduction of combination of Esmeron® and Nimbex® (Drug)
Phase: N/A
Status: Completed
Sponsored by: Yonsei University Official(s) and/or principal investigator(s): Young Gwan Cheon, Study Director, Affiliation: Institutional Review Board of Wonju Severance Christian Hospital
Summary
BACKGROUND: The combinations of rocuronium and cisatracurium have a synergic effect. The
investigators studied whether the prediction is possible to have a sufficient effect of
reducing the dose when combining the two neuromuscular blocking agents through monitoring
neuromuscular relaxation during surgery.
METHODS: Each group were intubating dose group (Group I, n=27) combined Effective Dose
(ED)95 rocuronium and ED95 cisatracurium, small amount reducing group (Group S, n=27)
reduced 10% of each ED95 and large amount reducing group (Group L, n=27) reduced 20% of each
ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were
prepared by a nurse who was not involved in this study. Each study drug was administrated to
the patient and timer was started with TOF-Watch® monitoring. Train-of-four (TOF) of the
ulnar nerve was used as setting of 2 Hz per 12 sec. The investigators checked time to TOF
ratio=0 (Onset), time to 1st TOF ratio>25% (Duration 25%) and TOF 25-75% (recovery index)
under total i. v. anesthesia (TIVA). One way ANOVA was used for statistical analysis (α=0. 05,
β=0. 2).
Clinical Details
Official title: Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Onset of neuromuscular blocking agents(NMBAs)Duration 25% of neuromuscular blocking agents(NMBAs) Recovery Index of neuromuscular blocking agents(NMBAs)
Secondary outcome: operation timeanesthetic time Addition/time ratio
Detailed description:
Introduction:
Rocuronium and cisatracurium are representative neuromuscular blocking agents used widely
because the former have features of fast onset of peak effect and short duration of muscle
relaxation relatively while the latter have comparatively long duration relaxation time and
break down by Hofmann elimination and ester hydrolysis. A combination of the two have a
synergic effect may be also used with either the priming method for rapid sequence
intubation. It would contribute both to determine the effective combination rate clinically
and to predict the pharmacokinetic characteristics that determine how much the synergistic
effect of this combination. The investigators studied whether the prediction is possible to
have a sufficient effect of reducing the dose when combining the two muscle relaxants
through monitoring muscle relaxation during surgery.
Materials and methods:
This study was conducted to 81 patients scheduled for elective mastoidectomy and
tympanoplasty after obtaining written informed consent. All patients included the American
Society of Anesthesiologists (ASA) physical status I-II, aged 20-60, BMI 20-30 kg/m2. The
exclusion criteria were as follows: a history of allergy to the study drugs, neuromuscular
disease, pregnancy or breast-feeding, preoperative medication of antipsychotics or
neuroleptics known to interact with non-depolarizing neuromuscular blocking agents (NMBAs),
serum creatinine level>1. 2 mg/dL, liver transaminase>40 U/L. Anthropometric variables such
as height, weight were measured in ward before surgery. BMI calculated as total body weight
divided by the squared height. Ideal body weight (IBW) was calculated by the formula of
Devine {50 kg + 2. 3 × (height [inch]-60) for man and 45. 5 kg + 2. 3 × (height [inch]-60) for
woman} and used to administrate NMBAs of initial dose. Lean body weight (LBW) was calculated
by the formula of James {LBW (men) = (1. 10 × Weight(kg)) - 128 × ( Weight2 / (100 ×
Height(m))2), (women) = (1. 07 × Weight(kg)) - 148 × ( Weight2 / (100 × Height(m))2)}.
Additive dose of NMBAs was administrated by LBW. Patients were randomly assigned to each
group by opening of sealed allocation envelope. Each group were intubating dose group (Group
I, n=27) combined ED95 rocuronium and ED95 cisatracurium, small amount reducing group (Group
S, n=27) reduced 10% of each ED95 and large amount reducing group (Group L, n=27) reduced
20% of each ED95.
Monitoring and Medication:
In the operating room, monitoring was accomplished to patients with a noninvasive blood
pressure, pulse oximetry, electrocardiography, thermometer, Bispectral Index (BIS VISTA
Monitoring System; Aspect Medical Systems Inc, Norwood, MA, USA), and T1/T4 ratio used
TOF-Watch® (Organon, Teknica B. V., Boxtel, the Netherlands). Every 5 min, measured things
are recorded.
Premedications with midazolam 2 mg and glycopyrrolate 0. 2 mg were administrated to patients
intramuscularly 1 h before surgery. Before patients arrived in the operating room,
rocuronium and cisatracurium were prepared by a nurse who was not involved in this study.
The syringe containing each study drug was conveyed to the performer of this study as the
status of shielding the scale. The syringes of rocuronium and cisatracurium used each other
syringe. Anesthesia was induced with propofol 1. 5-2. 5 mg/kg, remifentanil 0. 4-0. 6 mcg/kg,
afterward maintained with target controlled infusion (TCI) of propofol 5-10 mg/kg/hr and
remifentanil 0. 05-2 mcg/kg/min. The infusion pump (Orchestra Module DPS, Fresenius-Vial,
Brezins, France) was operated with Minto's and Marshall's pharmacokinetic model for effect
site TCI of remifentanil and propofol.
The opposite arm against operation side was used for neuromuscular monitoring and attached
to armboard of TOF-Watch®. Each study drug was administrated to the patient and timer was
started with T1/T4 ratio monitoring. The surface electrodes of ulnar nerve placed at the
wrist and Train-of-four (TOF) stimulation was used as setting of supramaximal square wave
impulses with 200μs duration, 2 Hz per 12sec. The investigators checked times to TOF ratio=0
(Onset), 1st TOF ratio>25% (Duration 25%) and TOF 25-75% (Recovery Index), recovery time of
90% (TOF 25-90%) under total i. v. anesthesia (TIVA). Also the investigators checked the rate
of additional rescue dose administrated with 10% of initial NMBAs dose, operation time from
incision to surgical wound dressing, anesthesia time from entering to going out the
operation room. Body temperature was maintained above 35°C using warm air blanket. The
arterial pressure cuff was placed on the opposite arm against TOF monitoring.
Adverse Events and Management:
In all patients, anesthesia level was assessed based on a BIS score of 40-60. Moderate
hypertension (>120% of baseline) or hypotension (<80% of baseline) was treated by increasing
or decreasing rate of propofol infusion with fluid supplement. Severe hemodynamic change
(systolic pressure < 90 mmHg or > 200 mmHg) was controlled by intravenous (IV)
administration of phenylephrine 50 mcg or nicardipine 250 mcg repeatedly until being
hemodynamic stable status. Unexpectedly, when hiccup or self-contained respiration was
showed, additional rescue dose of NMBAs was administrated to the patient even though T1/T4
ratio was lower than 25%.
Statistical Analysis:
All data are expressed as means ± standard deviations (SDs), numbers (percentages), or
medians (upper and lower quartiles), as appropriate. Data between the groups were compared
using the χ2 test, Fisher exact test, independent t test, or the Mann-Whitney U test, as
appropriate. To assess data normality, the Kolmogorov-Smirnov test was performed on the data
set. According to a preliminary study, 24 patients would be required in each group with a
power of 0. 9 and a type I error of 0. 05. Factoring in a drop-out rate of 10%, the
investigators calculated that 27 patients would be required for each group. All statistical
analyses were performed with the SPSS 18. 0 (SPSS Inc., Chicago, IL, USA) program. A P value
<0. 05 was considered statistically significant.
Eligibility
Minimum age: 20 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- the American Society of Anesthesiologists (ASA) physical status I-II
- BMI 20-30 kg/m2
- Patients scheduled for mastoidectomy and tympanoplasty.
Exclusion Criteria:
- a history of allergy to the study drugs,
- neuromuscular disease,
- pregnancy
- breast-feeding,
- preoperative medication of antipsychotics or neuroleptics known to interact with
NMBAs
- serum creatinine level>1. 2 mg/dL,
- liver transaminase>40 U/L.
Locations and Contacts
Additional Information
Related publications: Naguib M, Samarkandi AH, Ammar A, Elfaqih SR, Al-Zahrani S, Turkistani A. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Anesthesiology. 1998 Nov;89(5):1116-24. Erratum in: Anesthesiology 1999 Apr;90(4):1241. Donati F, Plaud B. Rocuronium-cisatracurium combinations. Anesthesiology. 1999 Aug;91(2):587-8. Miller DR, Wherrett C, Hull K, Watson J, Legault S. Cumulation characteristics of cisatracurium and rocuronium during continuous infusion. Can J Anaesth. 2000 Oct;47(10):943-9. Cammu G, de Baerdemaeker L, den Blauwen N, de Mey JC, Struys M, Mortier E. Postoperative residual curarization with cisatracurium and rocuronium infusions. Eur J Anaesthesiol. 2002 Feb;19(2):129-34. Hans P, Welter P, Dewandre PY, Brichant JF, Bonhomme V. Recovery from neuromuscular block after an intubation dose of cisatracurium and rocuronium in lumbar disc surgery. Acta Anaesthesiol Belg. 2004;55(2):129-33. Mak PH, Irwin MG. The effect of cisatracurium and rocuronium on cisatracurium precurarization and the priming principle. J Clin Anesth. 2004 Mar;16(2):83-7. Kopman AF, Zank LM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg. 2004 Jan;98(1):102-6, table of contents. de Morais BS, de Castro CH, Teixeira VC, Pinto AS. Residual neuromuscular block after rocuronium or cisatracurium. Rev Bras Anestesiol. 2005 Dec;55(6):622-30. English, Portuguese. Kopman AF, Kopman DJ, Ng J, Zank LM. Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. J Clin Anesth. 2005 Feb;17(1):30-5. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008 May;100(5):622-30. doi: 10.1093/bja/aen037. Epub 2008 Apr 2. Adamus M, Gabrhelik T, Marek O. Influence of gender on the course of neuromuscular block following a single bolus dose of cisatracurium or rocuronium. Eur J Anaesthesiol. 2008 Jul;25(7):589-95. doi: 10.1017/S026502150800402X. Epub 2008 Apr 11. Lin SP, Chang KY, Chen YJ, Lin SM, Chang WK, Chan KH, Ting CK. Priming with rocuronium to accelerate the onset time of cisatracurium during intubation. J Chin Med Assoc. 2009 Jan;72(1):15-9. doi: 10.1016/S1726-4901(09)70014-0. Amin AM, Mohammad MY, Ibrahim MF. Comparative study of neuromuscular blocking and hemodynamic effects of rocuronium and cisatracurium under sevoflurane or total intravenous anesthesia. Middle East J Anaesthesiol. 2009 Feb;20(1):39-51. Fassbender P, Geldner G, Blobner M, Hofmockel R, Rex C, Gautam S, Malhotra A, Eikermann M. Clinical predictors of duration of action of cisatracurium and rocuronium administered long-term. Am J Crit Care. 2009 Sep;18(5):439-45. doi: 10.4037/ajcc2009883. Lee H, Jeong S, Choi C, Jeong H, Lee S, Jeong S. Anesthesiologist's satisfaction using between cisatracurium and rocuronium for the intubation in the anesthesia induced by remifentanil and propofol. Korean J Anesthesiol. 2013 Jan;64(1):34-9. doi: 10.4097/kjae.2013.64.1.34. Epub 2013 Jan 21.
Starting date: March 2014
Last updated: July 12, 2015
|